8AAU | pdb_00008aau

LIM Domain Kinase 1 (LIMK1) bound to LIMKi3


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.74 Å
  • R-Value Free: 
    0.240 (Depositor), 0.268 (DCC) 
  • R-Value Work: 
    0.211 (Depositor) 
  • R-Value Observed: 
    0.213 (Depositor) 

Starting Model: experimental
View more details

wwPDB Validation 3D Report Full Report

Validation slider image for 8AAU

Ligand Structure Quality Assessment 


This is version 1.2 of the entry. See complete history

Literature

Development and Characterization of Type I, Type II, and Type III LIM-Kinase Chemical Probes.

Hanke, T.Mathea, S.Woortman, J.Salah, E.Berger, B.T.Tumber, A.Kashima, R.Hata, A.Kuster, B.Muller, S.Knapp, S.

(2022) J Med Chem 65: 13264-13287

  • DOI: https://doi.org/10.1021/acs.jmedchem.2c01106
  • Primary Citation Related Structures: 
    7QHG, 8AAU

  • PubMed Abstract: 

    LIMKs are important regulators of actin and microtubule dynamics, and they play essential roles in many cellular processes. Deregulation of LIMKs has been linked to the development of diverse diseases, including cancers and cognitive disabilities, but well-characterized inhibitors known as chemical probes are still lacking. Here, we report the characterization of three highly selective LIMK1/2 inhibitors covering all canonical binding modes (type I/II/III) and the structure-based design of the type II/III inhibitors. Characterization of these chemical probes revealed a low nanomolar affinity for LIMK1/2, and all inhibitors 1 ( LIMKi3 ; type I), 48 ( TH470 ; type II), and 15 ( TH257 ; type III) showed excellent selectivity in a comprehensive scanMAX kinase selectivity panel. Phosphoproteomics revealed remarkable differences between type I and type II inhibitors compared with the allosteric inhibitor 15 . In phenotypic assays such as neurite outgrowth models of fragile X-chromosome, 15 showed promising activity, suggesting the potential application of allosteric LIMK inhibitors treating this orphan disease.


  • Organizational Affiliation
    • Institute for Pharmaceutical Chemistry, Johann Wolfgang Goethe-University, Max-von-Laue-Str. 9, D-60438 Frankfurt am Main, Germany.

Macromolecule Content 

  • Total Structure Weight: 36.8 kDa 
  • Atom Count: 2,432 
  • Modeled Residue Count: 291 
  • Deposited Residue Count: 310 
  • Unique protein chains: 1

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
LIM domain kinase 1A [auth L]310Homo sapiensMutation(s): 0 
Gene Names: LIMK1LIMK
EC: 2.7.11.1
UniProt & NIH Common Fund Data Resources
Find proteins for P53667 (Homo sapiens)
Explore P53667 
Go to UniProtKB:  P53667
PHAROS:  P53667
GTEx:  ENSG00000106683 
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP53667
Sequence Annotations
Expand
Reference Sequence

Small Molecules

Ligands 4 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
LH0
(Subject of Investigation/LOI)

Query on LH0



Download:Ideal Coordinates CCD File
C [auth L]~{N}-[5-[2-[2,6-bis(chloranyl)phenyl]-5-[bis(fluoranyl)methyl]pyrazol-3-yl]-1,3-thiazol-2-yl]-2-methyl-propanamide
C17 H14 Cl2 F2 N4 O S
IVUGBSGLHRJSSP-UHFFFAOYSA-N
SO4

Query on SO4



Download:Ideal Coordinates CCD File
D [auth L],
E [auth L],
F [auth L]
SULFATE ION
O4 S
QAOWNCQODCNURD-UHFFFAOYSA-L
EDO

Query on EDO



Download:Ideal Coordinates CCD File
B [auth L]1,2-ETHANEDIOL
C2 H6 O2
LYCAIKOWRPUZTN-UHFFFAOYSA-N
MG

Query on MG



Download:Ideal Coordinates CCD File
G [auth L]MAGNESIUM ION
Mg
JLVVSXFLKOJNIY-UHFFFAOYSA-N

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.74 Å
  • R-Value Free:  0.240 (Depositor), 0.268 (DCC) 
  • R-Value Work:  0.211 (Depositor) 
  • R-Value Observed: 0.213 (Depositor) 
Space Group: P 61 2 2
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 85.668α = 90
b = 85.668β = 90
c = 182.108γ = 120
Software Package:
Software NamePurpose
PHENIXrefinement
MOSFLMdata reduction
Aimlessdata scaling
PHASERphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History 

& Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Not funded--

Revision History  (Full details and data files)

  • Version 1.0: 2022-08-10
    Type: Initial release
  • Version 1.1: 2023-02-22
    Changes: Database references
  • Version 1.2: 2024-02-07
    Changes: Data collection, Refinement description